Amendment to Development and Marketing Agreement between Boehringer Ingelheim International GmbH and InterMune Pharmaceuticals (August 2001)
This letter agreement amends the existing Development and Marketing Agreement between Boehringer Ingelheim International GmbH and InterMune Pharmaceuticals. The amendment expands the scope of the agreement to include ovarian cancer as a covered field and indication, and adds a specific clinical protocol for a combination therapy involving Actimmune®. Both parties agree to these changes by signing the letter. The amendment is effective upon acceptance and signature by both parties.
QuickLinks -- Click here to rapidly navigate through this document
EXHIBIT 10.40
Boehringer Ingelheim International GmbH | ||
| InterMune Pharmaceuticals 3280 Bayshore Blvd Brisbane, CA 94005 U.S.A. | ||
1 August 2001 | ||
Our reference CD Dr.Mi-mw | ||
Dr. David Mitchard Phone +49/61 32/77-34 08 Fax +49/61 32/77-35 83 E-Mail mitchard@ ing.boehringer-ingelheim.com Binger Strasse 173 55216 Ingelheim am Rhein Germany Phone +49/61 32/77-0 Fax +49/61 32/72-0 www.boehringer-ingelheim.com |
Development and Marketing Agreement dated March 23, 2001 (Agreement)
Dear Sirs
Words and expressions defined or interpreted in the Agreement shall have the same meanings and interpretations when used in this letter.
We propose the following changes to the Agreement:
- 1.10
- The definition Field is extended to include ovarian cancer (oc).
- 1.22
- The definition New Indications is extended to include oc.
- 1.25
- The definition Protocols is extended to include the clinical protocol dated 06/06/01 entitled
"Actimmune® (Interferon Gamma-1b) in Combination with Chemotherapy (Carboplatin / Paclitaxel) for First-line therapy of Advanced Ovarian or Primary Peritoneal Carcinoma"
which InterMune sent to BII with a letter dated June 14, 2001.
If you agree with the above, please signify your acceptance by signing and returning one original of this letter.
Yours faithfully BOEHRINGER INGELHEIM INTERNATIONAL GmbH ppa. | Accepted for and on behalf of InterMune Pharmaceuticals | |||
/s/ D. MITCHARD Dr. Mitchard | /s/ HUBER Dr. Huber | /s/ JOHN J. WULF by: John J. Wulf Sr. VP of Corporate Development | ||
Date: August 10, 2001 | ||||
QuickLinks
- EXHIBIT 10.40
